Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology

1

Sept 25 (Reuters) – Shares in Swedish drug-delivery company Nanexa more than doubled their value in early Friday trading after it signed a global licensing deal with Novo Nordisk worth up to about

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)